Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 5:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 9,138 matching trials from the live ClinicalTrials.gov search.
Filters: Rochester, Minnesota Clear all
Completed Phase 1 Interventional

Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors

NCT03102320
View directory record Official record
Conditions
Neoplasms
Interventions
Cisplatin, Gemcitabine, Anetumab ravtansine (BAY94-9343)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
13
States / cities
Phoenix, Arizona • Los Angeles, California • Stanford, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Oct 30, 2026, 5:35 PM EDT
Enrolling by invitation Phase 2 Interventional

Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Adults

NCT03675724
View directory record Official record
Conditions
Frail Elderly Syndrome
Interventions
Fisetin, Placebo oral capsule
Dietary Supplement · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
70 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 30, 2026, 5:35 PM EDT
Completed Phase 2 Interventional Results available

Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant Recipients

NCT00942305
View directory record Official record
Conditions
Cytomegalovirus Infection
Interventions
Brincidofovir, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
26
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2021 · Synced Oct 30, 2026, 5:35 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

NCT03898479
View directory record Official record
Conditions
Alopecia Areata
Interventions
CTP-543
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 30, 2026, 5:35 PM EDT
Completed Phase 2 Interventional Results available

Abrilumab (AMG 181) in Adults With Moderate to Severe Crohn's Disease

NCT01696396
View directory record Official record
Conditions
Crohn's Disease
Interventions
Abrilumab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
24
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Oct 30, 2026, 5:35 PM EDT
Completed Not applicable Interventional

Cardiac Sympathetic Activity in Patients With the Apical Ballooning Syndrome

NCT00586183
View directory record Official record
Conditions
Apical Ballooning Syndrome
Interventions
PET scan
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 4, 2008 · Synced Oct 30, 2026, 5:35 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas

NCT03504423
View directory record Official record
Conditions
Pancreatic Cancer Metastatic
Interventions
CPI 613, mFolfirinox, Folfirinox
Drug
Lead sponsor
Cornerstone Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
40
States / cities
Gilbert, Arizona • Tucson, Arizona • Duarte, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2023 · Synced Oct 30, 2026, 5:35 PM EDT
Completed Phase 3 Interventional Results available

Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ

NCT00438659
View directory record Official record
Conditions
Breast Cancer, Dermatologic Complications, Radiation Toxicity, Skin Reactions Secondary to Radiation Therapy
Interventions
mometasone furoate, placebo
Drug · Other
Lead sponsor
North Central Cancer Treatment Group
Network
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
189
States / cities
Aurora, Illinois • Bloomington, Illinois • Canton, Illinois + 116 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2016 · Synced Oct 30, 2026, 5:35 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Accelerated Resolution Therapy for Early Maladaptive Grief

NCT05624879
View directory record Official record
Conditions
Grief
Interventions
Accelerated Resolution Therapy, Information and Support
Behavioral · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
55 Years and older
Enrollment
440 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
4
States / cities
Phoenix, Arizona • Clearwater, Florida • Jacksonville, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 30, 2026, 5:35 PM EDT
Withdrawn Phase 3 Interventional

Fresh-Frozen Plasma Infusions to Reduce Risk of Bleeding Related to Invasive Procedures

NCT00233246
View directory record Official record
Conditions
Blood Coagulation Disorders
Interventions
FFP Infusion
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
4 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
15
States / cities
Atlanta, Georgia • Iowa City, Iowa • Baltimore, Maryland + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2014 · Synced Oct 30, 2026, 5:35 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02713386
View directory record Official record
Conditions
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, FIGO Stage III Ovarian Cancer 2014, FIGO Stage IIIA Ovarian Cancer 2014, FIGO Stage IIIA1 Ovarian Cancer, FIGO Stage IIIA2 Ovarian Cancer, FIGO Stage IIIB Ovarian Cancer 2014, FIGO Stage IIIC Ovarian Cancer 2014, FIGO Stage IVA Ovarian Cancer 2014, FIGO Stage IVB Ovarian Cancer 2014, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Stage III Fallopian Tube Cancer AJCC v7, Stage III Primary Peritoneal Cancer AJCC v7, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7
Interventions
Carboplatin, Paclitaxel, Ruxolitinib Phosphate, Therapeutic Conventional Surgery
Drug · Procedure
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
110
States / cities
Goodyear, Arizona • Auburn, California • Los Angeles, California + 87 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 30, 2026, 5:35 PM EDT
Recruiting Not applicable Interventional

ALLIANCE AVIV: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve in Failing Aortic Bioprosthetic Valves

NCT05172973
View directory record Official record
Conditions
Aortic Valve Insufficiency, Aortic Valve Stenosis
Interventions
SAPIEN X4/X4S THV
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2039
U.S. locations
34
States / cities
Newport Beach, California • San Francisco, California • Stanford, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 30, 2026, 5:35 PM EDT
Completed No phase listed Observational

Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)

NCT03289273
View directory record Official record
Conditions
Liver Neoplasms
Interventions
Regorafenib (Stivarga, BAY73-4506)
Drug
Lead sponsor
Bayer
Industry
Eligibility
Not listed
Enrollment
1,010 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
17
States / cities
Gilbert, Arizona • Phoenix, Arizona • Gainesville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2023 · Synced Oct 30, 2026, 5:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Immune Response to Pneumococcal Polysaccharide Vaccine (23-valent) Predicts Asthma Status and Outcomes in Late Adolescents With Asthma

NCT02719379
View directory record Official record
Conditions
Asthma
Interventions
Pneumonococcal Polysaccharide Vaccine 23-valent (PPSV-23)
Biological
Lead sponsor
Rohit Divekar
Other
Eligibility
19 Years to 20 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 11, 2017 · Synced Oct 30, 2026, 5:35 PM EDT
Completed Phase 2 Interventional Results available

Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers

NCT05641896
View directory record Official record
Conditions
Gastrointestinal Cancers, Cholangiocarcinoma, Gastric Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Hepatocellular Carcinoma
Interventions
[18F]FAPI-74 PET/CT
Drug
Lead sponsor
SOFIE
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Los Angeles, California • Boston, Massachusetts • Grand Rapids, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 30, 2026, 5:35 PM EDT
Completed Not applicable Interventional Results available

CONNECT Study - Clinical Evaluation Of Remote NotificatioN to rEduCe Time to Clinical Decision

NCT00402246
View directory record Official record
Conditions
Arrhythmia, Tachycardia, Atrial Fibrillation, Ventricular Fibrillation
Interventions
Remote Management, In-Office Care
Other
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
18 Years and older
Enrollment
2,009 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
127
States / cities
Mobile, Alabama • Mesa, Arizona • Scottsdale, Arizona + 124 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2011 · Synced Oct 30, 2026, 5:35 PM EDT
Recruiting Phase 1Phase 2 Interventional

Proton or Photon RT for Retroperitoneal Sarcomas

NCT01659203
View directory record Official record
Conditions
Retroperitoneal Sarcoma
Interventions
IG-IMPT, IG IMRT
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
10
States / cities
Chicago, Illinois • Boston, Massachusetts • Rochester, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 30, 2026, 5:35 PM EDT
Completed No phase listed Observational

Capsaicin Cough Threshold in Chronic Cough Due to Postnasal Drip

NCT00588627
View directory record Official record
Conditions
Post Nasal Drip
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 10, 2010 · Synced Oct 30, 2026, 5:35 PM EDT
Completed Phase 3 Interventional Results available

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCH CD3-OLS)

NCT03931941
View directory record Official record
Conditions
Clostridium Difficile Infection, Infection, Communicable Diseases
Interventions
RBX2660
Drug
Lead sponsor
Rebiotix Inc.
Industry
Eligibility
18 Years and older
Enrollment
793 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
46
States / cities
Phoenix, Arizona • North Little Rock, Arkansas • Oxnard, California + 43 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Oct 30, 2026, 5:35 PM EDT
Terminated Phase 2 Interventional Results available

Hemodynamic and Echocardiographic Assessment of Riociguat Effects on Myocardial Wall Contractility and Relaxation Kinetics

NCT01065051
View directory record Official record
Conditions
Hypertension, Pulmonary, Ventricular Dysfunction, Left
Interventions
Riociguat (Adempas, BAY63-2521), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 30, 2026, 5:35 PM EDT
Completed Phase 2 Interventional Results available

Does Early Administration of Tranexamic Acid Reduce Blood Loss and Perioperative Transfusion Requirement

NCT03182751
View directory record Official record
Conditions
Hip Fractures, Intertrochanteric Fractures
Interventions
Tranexamic Acid (TXA), Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 30, 2023 · Synced Oct 30, 2026, 5:35 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer

NCT05232851
View directory record Official record
Conditions
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Carcinoma, Locally Advanced Oropharyngeal Carcinoma, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions
Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101, Pembrolizumab, Computed Tomography, FDG-Positron Emission Tomography, Biospecimen Collection, Biopsy
Biological · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 30, 2026, 5:35 PM EDT
Completed Phase 3 Interventional Results available

HALT Progression of Polycystic Kidney Disease Study B

NCT01885559
View directory record Official record
Conditions
Kidney, Polycystic
Interventions
Lisinopril, Telmisartan, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
15 Years to 64 Years
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
7
States / cities
Aurora, Colorado • Atlanta, Georgia • Kansas City, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2020 · Synced Oct 30, 2026, 5:35 PM EDT
Completed Not applicable Interventional

Rapid On Site Evaluation of Pleural Touch Preparations in Diagnosing Malignant Pleural Effusion in Patients Undergoing Pleuroscopy

NCT03868579
View directory record Official record
Conditions
Malignant Neoplasm, Malignant Respiratory Tract Neoplasm, Malignant Thoracic Neoplasm
Interventions
Biopsy, Medical Chart Review, Thoracoscopy
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
3
States / cities
Rochester, Minnesota • Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Oct 30, 2026, 5:35 PM EDT